Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements

Bulletin Express04-01

Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026.

The company’s authorised share capital stood at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each—identical to the previous month.

Issued share capital was steady at 9.15 billion ordinary shares, while treasury shares were unchanged at 184.01 million. Consequently, the total number of shares in issue, including treasury shares, remained 9.33 billion.

No new shares were issued, repurchased, or cancelled during the month. Likewise, no treasury shares were transferred or sold. Total funds raised from option exercises were HKD 0.

Outstanding share options under the 24 October 2017 schemes were unchanged: 60.59 million options exercisable at HKD 0.972 and 7.50 million options at HKD 2.22. The aggregate pool of shares that may be issued upon future option grants under the schemes remained at 844.95 million.

Management confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 March 2026.

The filing was submitted by Executive Director and Joint Company Secretary Ms. Chen Yanling on 1 April 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166458779?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166458779","market":"hk","top_or_hot":-1,"title":"Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements","media":"Bulletin Express","content":"<p>Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026.</p>\n<p>The company’s authorised share capital stood at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each—identical to the previous month.</p>\n<p>Issued share capital was steady at 9.15 billion ordinary shares, while treasury shares were unchanged at 184.01 million. Consequently, the total number of shares in issue, including treasury shares, remained 9.33 billion.</p>\n<p>No new shares were issued, repurchased, or cancelled during the month. Likewise, no treasury shares were transferred or sold. Total funds raised from option exercises were HKD 0.</p>\n<p>Outstanding share options under the 24 October 2017 schemes were unchanged: 60.59 million options exercisable at HKD 0.972 and 7.50 million options at HKD 2.22. The aggregate pool of shares that may be issued upon future option grants under the schemes remained at 844.95 million.</p>\n<p>Management confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 March 2026.</p>\n<p>The filing was submitted by Executive Director and Joint Company Secretary Ms. Chen Yanling on 1 April 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSihuan Pharma: March 2026 Share Capital Stable, No New Issuances or Treasury Movements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-01 16:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026.</p>\n<p>The company’s authorised share capital stood at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each—identical to the previous month.</p>\n<p>Issued share capital was steady at 9.15 billion ordinary shares, while treasury shares were unchanged at 184.01 million. Consequently, the total number of shares in issue, including treasury shares, remained 9.33 billion.</p>\n<p>No new shares were issued, repurchased, or cancelled during the month. Likewise, no treasury shares were transferred or sold. Total funds raised from option exercises were HKD 0.</p>\n<p>Outstanding share options under the 24 October 2017 schemes were unchanged: 60.59 million options exercisable at HKD 0.972 and 7.50 million options at HKD 2.22. The aggregate pool of shares that may be issued upon future option grants under the schemes remained at 844.95 million.</p>\n<p>Management confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 March 2026.</p>\n<p>The filing was submitted by Executive Director and Joint Company Secretary Ms. Chen Yanling on 1 April 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00460","symbol_name":"四环医药","start_time":0,"source_url":"","article_id":"1166458779","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166458779","pubTimestamp":1775031904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026. The company’s authorised share capital stood at HKD 1.00 billion,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00460":"四环医药"},"translate_title":"四环医药：2026年3月股本稳定，无新发行或库务变动","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00460":1},"content_text":"Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharma) reported that its share capital structure remained unchanged in March 2026.\nThe company’s authorised share capital stood at HKD 1.00 billion, representing 100.00 billion ordinary shares with a par value of HKD 0.01 each—identical to the previous month.\nIssued share capital was steady at 9.15 billion ordinary shares, while treasury shares were unchanged at 184.01 million. Consequently, the total number of shares in issue, including treasury shares, remained 9.33 billion.\nNo new shares were issued, repurchased, or cancelled during the month. Likewise, no treasury shares were transferred or sold. Total funds raised from option exercises were HKD 0.\nOutstanding share options under the 24 October 2017 schemes were unchanged: 60.59 million options exercisable at HKD 0.972 and 7.50 million options at HKD 2.22. The aggregate pool of shares that may be issued upon future option grants under the schemes remained at 844.95 million.\nManagement confirmed compliance with the Main Board’s minimum 25 % public-float requirement as of 31 March 2026.\nThe filing was submitted by Executive Director and Joint Company Secretary Ms. Chen Yanling on 1 April 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166458779","isCrawlerRequest":true}